Lexaria Bioscience Ratios and Metrics

Market cap in millions USD. Fiscal year is September - August.

Millions USD. Fiscal year is Sep - Aug.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 23, 2026	Aug '25 Aug 31, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023	Aug '22 Aug 31, 2022	Aug '21 Aug 31, 2021
Market Cap	14	17	62	8	18	36
Market Cap Growth	-20.38%	-72.15%	627.59%	-51.77%	-50.55%	-
Enterprise Value	9.27	14.99	55.02	6.82	11.19	23.76
Last Close Price	0.56	0.88	3.91	1.05	2.96	6.22
PS Ratio	39.26	24.39	133.15	37.56	68.97	49.28
PB Ratio	2.20	5.76	7.69	2.79	2.22	2.69
P/TBV Ratio	1.86	5.91	6.44	2.69	2.34	2.12
EV/Sales Ratio	25.19	21.24	118.52	30.15	43.81	32.88
Debt / Equity Ratio	0.01	0.03	0.01	0.05	0.00	0.00
Net Debt / Equity Ratio	-0.78	-0.61	-0.80	-0.43	-0.77	-0.88
Net Debt / EBITDA Ratio	0.55	0.16	1.13	0.21	0.94	2.09
Net Debt / FCF Ratio	0.55	0.18	1.28	0.22	1.24	2.92
Asset Turnover	0.06	0.11	0.08	0.04	0.02	0.09
Inventory Turnover	-	-	-	1.64	2.11	2.39
Quick Ratio	24.74	1.55	6.10	6.21	32.79	78.90
Current Ratio	26.88	2.32	7.18	8.03	35.96	81.18
Return on Equity (ROE)	-56.75%	-232.15%	-112.36%	-130.18%	-71.35%	-53.57%
Return on Assets (ROA)	-150.97%	-182.18%	-96.27%	-119.69%	-62.74%	-70.67%
Return on Invested Capital (ROIC)	-1079.16%	-1179.60%	-439.84%	-452.15%	-451.56%	-400.77%
Return on Capital Employed (ROCE)	-174.19%	-227.38%	-108.71%	-124.98%	-63.79%	-72.37%
Buyback Yield / Dilution	-31.30%	-45.34%	-87.24%	-12.38%	-34.02%	-58.34%
Total Shareholder Return	-31.30%	-45.34%	-87.24%	-12.38%	-34.02%	-58.34%

SEC Filings: 10-K · 10-Q